| 发明名称 | Modified VP1-capsid protein of parvovirus B19 | ||
| 摘要 | The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1. | ||
| 申请公布号 | US9573979(B2) | 申请公布日期 | 2017.02.21 |
| 申请号 | US200511575951 | 申请日期 | 2005.09.23 |
| 申请人 | Modrow Susanne;Lowin Torsten;Mobs Markus;Broker Michael | 发明人 | Modrow Susanne;Lowin Torsten;Mobs Markus;Broker Michael |
| 分类号 | C07K14/005;A61K38/00;A61K38/16 | 主分类号 | C07K14/005 |
| 代理机构 | Wolf, Greenfield & Sacks, P.C. | 代理人 | Wolf, Greenfield & Sacks, P.C. |
| 主权项 | 1. A pharmaceutical composition comprising a modified VP1-capsid protein of parvovirus B19, wherein a wild type sequence of the VP-1 capsid protein has been modified to contain amino acid substitutions at positions corresponding to histidine 153 of SEQ ID NO:1, tyrosine 157 of SEQ ID NO:1, lysine 162 of SEQ ID NO:1, and tyrosine 168 of SEQ ID NO:1, wherein said substitutions are histidine 153 to alanine, tyrosine 157 to phenylalanine, lysine 162 to leucine, and tyrosine 168 to phenylalanine, and wherein said modified VP1-capsid protein has a reduced phospholipase A2 enzyme activity as compared to the wild type VP1-capsid protein. | ||
| 地址 | Altenthann DE | ||